



Information for Vermont Prescribers of Prescription Drugs 2024

SYMPROIC ® (naldemedine tablets for oral use)

- This list does not imply that the products on this chart are interchangeable or have the same efficacy or safety. Please refer to each product's FDA-approved label and indication for further information.
- The prices listed below are Average Wholesale Prices ("AWP") as established and made available to the public by a third-party publisher. The price paid by consumers may be higher or lower than the prices listed below. Information about AWP of these drugs is being provided to Vermont prescribers pursuant to Vermont law, to give you information about the relative prices of marketed drugs and other drugs in the same therapeutic class.
- The prices listed here do not necessarily reflect price per dosage, price per course of treatment or the cost effectiveness, of all the products listed. For simplicity, only the smallest package sizes available for each product are included.

| Product Name | Labeler | NDC/UPC/HRI | AWP | | |
|--|--------------------------------|---------------|-----|-------------|------------|
| | | | Pkg | Pack | Tablet |
| Marketed Product | | | | | |
| Symproic Oral Tablet 0.2 MG | BIODELIVERY SCIENCES | 59385-0041-30 | 30 | \$555.30 | \$18.51 |
| Other Products | | | | | |
| Product Name | Labeler | NDC/UPC/HRI | Pkg | Pack | Tablet |
| Alli Oral Capsule 60 MG | GLAXO CONSUMER HEALTHCARE L.P. | 00135-0461-01 | 21 | \$19.10 | \$0.46 |
| Alvimopan Oral Capsule 12 MG | ACTAVIS PHARMA | 00591-2312-15 | 30 | \$6,218.93 | \$207.30 |
| Bylvay (Pellets) Oral Capsule Sprinkle 200 MCG | ALBIREO PHARMA | 74528-0020-01 | 30 | \$8,688.00 | \$289.60 |
| Bylvay (Pellets) Oral Capsule Sprinkle 600 MCG | ALBIREO PHARMA | 74528-0060-01 | 30 | \$26,064.00 | \$868.80 |
| Bylvay Oral Capsule 1200 MCG | ALBIREO PHARMA | 74528-0120-01 | 30 | \$52,128.00 | \$1,737.60 |
| Bylvay Oral Capsule 400 MCG | ALBIREO PHARMA | 74528-0040-01 | 30 | \$17,376.00 | \$579.20 |
| Cholbam Oral Capsule 250 MG | MIRUM PHARMACEUTICALS | 45043-0002-02 | 90 | \$95,018.40 | \$1,055.76 |
| Cholbam Oral Capsule 50 MG | MIRUM PHARMACEUTICALS | 45043-0001-02 | 90 | \$31,576.80 | \$350.85 |
| Entereg Oral Capsule 12 MG | MERCK SHARP & DOHME | 67919-0020-10 | 30 | \$6,546.24 | \$218.21 |
| Gattex Subcutaneous Kit 5 MG | SHIRE US INC. | 68875-0102-01 | 1 | N/A | N/A |
| Ibsrela Oral Tablet 50 MG | ARDELYX | 73154-0050-60 | 60 | \$2,143.20 | \$35.72 |



| | | | | | |
|--|-------------------------------|---------------|-----|-------------|----------|
| Linzezz Oral Capsule 145 MCG | ALLERGAN | 00456-1201-30 | 30 | \$649.10 | \$21.64 |
| Linzezz Oral Capsule 290 MCG | ALLERGAN | 00456-1202-30 | 30 | \$649.10 | \$21.64 |
| Linzezz Oral Capsule 72 MCG | ALLERGAN | 00456-1203-30 | 30 | \$649.10 | \$21.64 |
| Livmarli Oral Solution 9.5 MG/ML | MIRUM PHARMACEUTICALS | 79378-0110-01 | 30 | N/A | N/A |
| Lubiprostone Oral Capsule 24 MCG | AMNEAL PHARMACEUTICALS | 65162-0842-06 | 60 | \$400.76 | \$6.68 |
| Lubiprostone Oral Capsule 24 MCG | DR.REDDY'S LABORATORIES, INC. | 43598-0168-60 | 60 | \$400.76 | \$6.68 |
| Lubiprostone Oral Capsule 24 MCG | PAR PHARMACEUTICAL | 00254-3029-02 | 60 | \$400.76 | \$6.68 |
| Lubiprostone Oral Capsule 24 MCG | SUN PHARMACEUTICALS | 63304-0352-60 | 60 | \$400.76 | \$6.68 |
| Lubiprostone Oral Capsule 24 MCG | TEVA PHARMACEUTICALS | 00480-4138-06 | 60 | \$423.05 | \$7.05 |
| Lubiprostone Oral Capsule 24 MCG | ZYDUS PHARMACEUTICALS (USA) | 70710-1642-06 | 60 | \$400.76 | \$6.68 |
| Lubiprostone Oral Capsule 8 MCG | AMNEAL PHARMACEUTICALS | 65162-0841-06 | 60 | \$400.76 | \$6.68 |
| Lubiprostone Oral Capsule 8 MCG | DR.REDDY'S LABORATORIES, INC. | 43598-0163-60 | 60 | \$400.76 | \$6.68 |
| Lubiprostone Oral Capsule 8 MCG | PAR PHARMACEUTICAL | 00254-3028-02 | 60 | \$400.76 | \$6.68 |
| Lubiprostone Oral Capsule 8 MCG | SUN PHARMACEUTICALS | 63304-0351-60 | 60 | \$400.76 | \$6.68 |
| Lubiprostone Oral Capsule 8 MCG | TEVA PHARMACEUTICALS | 00480-3479-06 | 60 | \$423.05 | \$7.05 |
| Lubiprostone Oral Capsule 8 MCG | ZYDUS PHARMACEUTICALS (USA) | 70710-1641-06 | 60 | \$400.76 | \$6.68 |
| Motegrity Oral Tablet 1 MG | SHIRE US INC. | 54092-0546-01 | 30 | \$636.80 | \$21.23 |
| Motegrity Oral Tablet 2 MG | SHIRE US INC. | 54092-0547-01 | 30 | \$636.80 | \$21.23 |
| Movantik Oral Tablet 12.5 MG | VALINOR PHARMA | 82625-8801-01 | 30 | \$498.73 | \$16.62 |
| Movantik Oral Tablet 25 MG | VALINOR PHARMA | 82625-8802-01 | 30 | \$498.73 | \$16.62 |
| Ocaliva Oral Tablet 10 MG | INTERCEPT PHARMACEUTICALS | 69516-0010-30 | 30 | \$10,826.12 | \$360.87 |
| Ocaliva Oral Tablet 5 MG | INTERCEPT PHARMACEUTICALS | 69516-0005-30 | 30 | \$10,826.12 | \$360.87 |
| Orlistat Oral Capsule 120 MG | H2 PHARMA | 61269-0565-90 | 90 | \$780.58 | \$8.67 |
| Orlistat Powder | DARMERICA | 71052-0110-10 | 100 | N/A | N/A |
| Relistor Oral Tablet 150 MG | BAUSCH HEALTH US | 65649-0150-90 | 90 | \$2,857.31 | \$31.75 |
| Relistor Subcutaneous Solution 12 MG/0.6ML | BAUSCH HEALTH US | 65649-0551-02 | 0.6 | N/A | N/A |
| Relistor Subcutaneous Solution 8 MG/0.4ML | BAUSCH HEALTH US | 65649-0552-04 | 0.4 | N/A | N/A |
| Skyrizi Intravenous Solution 600 MG/10ML | ABBVIE | 00074-5015-01 | 10 | N/A | N/A |
| Skyrizi Subcutaneous Solution Cartridge 180 MG/1.2ML | ABBVIE | 00074-1065-01 | 1.2 | N/A | N/A |
| Skyrizi Subcutaneous Solution Cartridge 360 MG/2.4ML | ABBVIE | 00074-1069-01 | 2.4 | N/A | N/A |
| Stelara Intravenous Solution 130 MG/26ML | JANSSSEN BIOTECH | 57894-0054-27 | 26 | N/A | N/A |



| | | | | | |
|-----------------------------|------------------|---------------|----|------------|---------|
| Trulance Oral Tablet 3 MG | BAUSCH HEALTH US | 65649-0003-30 | 30 | \$669.67 | \$22.32 |
| Viberzi Oral Tablet 100 MG | ALLERGAN | 61874-0100-60 | 60 | \$1,921.55 | \$32.03 |
| Viberzi Oral Tablet 75 MG | ALLERGAN | 61874-0075-60 | 60 | \$1,921.55 | \$32.03 |
| Xenical Oral Capsule 120 MG | H2 PHARMA | 61269-0460-90 | 90 | \$904.45 | \$10.05 |

Products with “N/A” in price information are “non-pill” products.

Medi-Span Price Rx Pro is the source for this information.

January 12, 2024